Asset Details
Do you wish to reserve the book?
Noncoding RNAs in gastric cancer: implications for drug resistance
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Noncoding RNAs in gastric cancer: implications for drug resistance
Do you wish to request the book?
Noncoding RNAs in gastric cancer: implications for drug resistance
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Noncoding RNAs in gastric cancer: implications for drug resistance
2020
Overview
Gastric cancer is the fourth most common malignancy and the third leading cause of cancer-related deaths worldwide. Advanced gastric cancer patients can notably benefit from chemotherapy including adriamycin, platinum drugs, 5-fluorouracil, vincristine, and paclitaxel as well as targeted therapy drugs. Nevertheless, primary drug resistance or acquisition drug resistance eventually lead to treatment failure and poor outcomes of the gastric cancer patients. The detailed mechanisms involved in gastric cancer drug resistance have been revealed. Interestingly, different noncoding RNAs (ncRNAs), such as microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs), are critically involved in gastric cancer development. Multiple lines of evidences demonstrated that ncRNAs play a vital role in gastric cancer resistance to chemotherapy reagents and targeted therapy drugs. In this review, we systematically summarized the emerging role and detailed molecular mechanisms of ncRNAs impact drug resistance of gastric cancer. Additionally, we propose the potential clinical implications of ncRNAs as novel therapeutic targets and prognostic biomarkers for gastric cancer.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
Subject
/ Animals
/ Avelumab
/ Biomarkers, Tumor - genetics
/ Biomedical and Life Sciences
/ DNA
/ Drug Resistance, Neoplasm - genetics
/ Gene Expression Regulation, Neoplastic
/ Humans
/ MicroRNA
/ Non-coding RNAs and RNA modifiers in cancer progression and cancer cells resistance to therapies
/ Novels
/ Oncology
/ Proteins
/ Review
/ RNA
/ RNA, Long Noncoding - genetics
/ Stomach Neoplasms - drug therapy
/ Stomach Neoplasms - genetics
